About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
Adequate CD19-positive cell content is required to reliably identify both dominant and subclonal TP53 mutations. DNA was isolated in parallel from 2 different sample types from this patient: ...
How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...
BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...
When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...
Ibrutinib is effective for R/R CLL, with a median follow-up of 42.2 months, confirming its role in prolonged disease control. Factors like older age, previous therapies, and double-hit TP53 ...
ATM mutations alone do not predict early treatment need in chronic lymphocytic leukemia, study finds
In chronic lymphocytic leukemia (CLL), certain recurrent genetic alterations are known to influence disease progression and survival. One important abnormality is the loss of part of chromosome 11, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results